VBI Vaccines
Blood & Organ Banks · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
160 2nd St Ste 3, Cambridge, Massachuset...Phone Number
(617) 830-3031Website
www.vbivaccines.comRevenue
$9.4 MillionStock Symbol
VBIVIndustry
ZI Rank: 3
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
4
3
3
3
3
About VBI Vaccines
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary ofRead more
VBI Vaccines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VBI Vaccines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when VBI Vaccines launches new products
Check out if VBI Vaccines is spiking on competitors!
Funding: Get notified immidiatlly once VBI Vaccines has new funding data
VBI Vaccines, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if VBI Vaccines had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at VBI Vaccines
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on VBI Vaccines recently announced quarterly report
Check if VBI Vaccines has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined VBI Vaccines as Masked Content
Find 3 more new buyers
Compare Similar Companies to VBI Vaccines
Compare insights from companies similar to VBI Vaccines, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
VBI Vaccines is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
VBI Vaccines is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about VBI Vaccines.
VBI Vaccines financials insights
Gather financial insights about VBI Vaccines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Debt
$3.5M
Debt
$2.2M
2012
Debt
$1.2M
2013
Multiple Rounds
$3.1M
2014
Debt
$1.5M
2016
Debt
$13M
2020
Debt
$50M
2022
Debt
$100M
VBI Vaccines Tech Stack
A closer look at the technologies used by VBI Vaccines
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Facilities Relocation / Expansion
VBI Vaccines is planning to move offices in July 2025. The move will impact employees at the existing office located at 160 Second Street, 3rd Floor, Cambridge, MA.
Facilities Relocation/Expansion
Pain Point
Pain Point, Bankruptcy
Earnings
Digital Marketing, Product Marketing, Marketing Automation, Automation, Funding
Earnings
Product Development, Research & Development, Information Technology
VBI Vaccines News & Media
Brii Bio Acquires Full Rights to BRII-179 HBV Drug from VBI Vaccines in $18M Strategic Deal
Brii Bio secures complete IP rights for BRII-179 hepatitis B treatment, eliminating future royalties and ensuring uninterrupted clinical supply as Phase 2b trials advance.Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV functional cure DURHAM, N.C. and BEIJING,...VBI Vaccines Provides an Update on its Restructuring Proceedings and Announces Partial Revocation Order from the British Columbia Securities Commission
CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ - VBI Vaccines Inc. ("VBI" or the "Company") today provided an update on the restructuring proceedings announced on July 30, 2024. Restructuring Transaction Following the conclusion of the sale and investment solicitation process conducted...VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (VBI) is initiating a voluntary nationwide recall of all remaining PreHevbrio® [Hepatitis B Vaccine (Recombinant); NDC 75052-001-10] (“PreHevbrio”) due to the bankruptcy of the company and termination of operations. Further distribution or use of any remaining PreHevbrio vaccine by healthcare providers or others must cease immediately. VBI Vaccines Inc. and its affiliates commenced a proceeding under Canada’s Companies’ Creditors Arrangement
Read more news
Top Blood & Organ Banks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VBI Vaccines
Sign Up For FreeTo access detailed company insights
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology... Read More
